U.S. markets open in 7 hours 39 minutes
  • S&P Futures

    4,120.75
    -3.75 (-0.09%)
     
  • Dow Futures

    32,721.00
    -16.00 (-0.05%)
     
  • Nasdaq Futures

    13,013.25
    -18.25 (-0.14%)
     
  • Russell 2000 Futures

    1,912.30
    -2.30 (-0.12%)
     
  • Crude Oil

    89.90
    -0.60 (-0.66%)
     
  • Gold

    1,806.10
    -6.20 (-0.34%)
     
  • Silver

    20.36
    -0.12 (-0.57%)
     
  • EUR/USD

    1.0219
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    2.7970
    0.0000 (0.00%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2083
    +0.0007 (+0.06%)
     
  • USD/JPY

    134.9590
    -0.1570 (-0.12%)
     
  • BTC-USD

    22,918.20
    -969.60 (-4.06%)
     
  • CMC Crypto 200

    532.17
    -25.18 (-4.52%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,808.74
    -191.22 (-0.68%)
     

Global Real World Evidence Solutions Market (2022 to 2030) - Share, Size, Trends, Industry Analysis Report

·8 min read

DUBLIN, May 4, 2022 /PRNewswire/ -- The "Real World Evidence Solutions Market Share, Size, Trends, Industry Analysis Report, By Component; By Therapeutic Areas : By End-User; By Region; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

RnMs Logo
RnMs Logo

The global real world evidence solutions market size is expected to reach USD 3.96 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

With regulatory authorities encouraging RWE solutions, the global evidence results industry will likely grow significantly throughout the forecast period. Regulators use RWE to observe the security of marketed pharmaceuticals by combining traditional pharmacovigilance approaches with modern digital tools.

Legislators also recognize the significance of RWE. It encourages patient-centered medication development and has improved clinical trial design and review. Regulators also indicate a desire for RWE to play a prominent role in their operations. However, industry growth is likely to be spurred by drug development delays, which would increase development costs.

Further, RWE is used by regulatory agencies to monitor the safety of packaged goods using traditional pharmacovigilance tools and newer digital tools such as the FDA Sentinel Initiative, a comment active safety surveillance system. RWE is presently being utilized in pre-approved efficacy decisions. It can be used more extensively in oncology, uncommon diseases, and pediatric ailments where randomized controlled clinical trials are impractical or unethical. Simultaneously, legislators realize the importance of RWE.

Based on the end-user, the pharmaceutical and medical devices segment accounted for the leading share in the industry in 2021. This segment is also expected to increase at the fastest rate over the projected period. This end-user segment's substantial share and rapid expansion can be related to the growing use of RWE studies in medication approvals and the increasing requirement to evaluate drug performance in world situations.

Industry players such as Clinigen Group plc, CLARIVATE PLC, Cognizant Technology Solution Corporation, PerkinElmer Inc., IBM Corporation, Flatiron Health Inc., ICON plc, IQVIA Holdings Inc., Medpace Holdings Inc., PAREXEL International Corporation, Oracle Corporation, PPD Inc., Symphony Innovation LLC, SAS Institute Inc., SYNEOS HEALTH Inc., and UnitedHealth Group Incorporated are key players operating in the global industry.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources

4. Global Real World Evidence Solutions Market Insights
4.1. Real World Evidence Solutions - Industry Snapshot
4.2. Real World Evidence Solutions Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Support from regulatory bodies for the use of RWE solutions
4.2.1.2. Rising focus on end-to-end RWE services
4.2.2. Restraints and Challenges
4.2.2.1. Reluctance to rely on real-world studies
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Real World Evidence Solutions Market Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Real World Evidence Solutions Market, by Component
5.1. Key Findings
5.2. Introduction
5.2.1. Global Real World Evidence Solutions Market, by Component, 2018 - 2030 (USD Billion)
5.3. DataSets
5.3.1. Global Real World Evidence Solutions Market, by DataSets, by Region, 2018 - 2030 (USD Billion)
5.3.2. Disparate Datasets
5.3.2.1. Global Real World Evidence Solutions Market, by Disparate Datasets, by Region, 2018 - 2030 (USD Billion)
5.3.2.2. HER/Clinical setting data
5.3.2.2.1. Global Real World Evidence Solutions Market, by HER/Clinical setting data, by Region, 2018 - 2030 (USD Billion)
5.3.2.3. Claims and billing data
5.3.2.3.1. Global Real World Evidence Solutions Market, by Claims and billing data, by Region, 2018 - 2030 (USD Billion)
5.3.2.4. Pharmacy data
5.3.2.4.1. Global Real World Evidence Solutions Market, by Pharmacy data, by Region, 2018 - 2030 (USD Billion)
5.3.2.5. Patient powered data
5.3.2.5.1. Global Real World Evidence Solutions Market, by Patient powered data, by Region, 2018 - 2030 (USD Billion)
5.3.2.6. Other Datasets
5.3.2.6.1. Global Real World Evidence Solutions Market, by Other Datasets, by Region, 2018 - 2030 (USD Billion)
5.3.3. Integrated datasets
5.3.3.1. Global Real World Evidence Solutions Market, by Integrated datasets, by Region, 2018 - 2030 (USD Billion)
5.4. Consulting and Analytic
5.4.1. Global Real World Evidence Solutions Market, by Consulting and Analytic, by Region, 2018 - 2030 (USD Billion)

6. Global Real World Evidence Solutions Market, by Therapeutic Areas
6.1. Key Findings
6.2. Introduction
6.2.1. Global Real World Evidence Solutions Market, by Therapeutic Areas, 2018 - 2030 (USD Billion)
6.3. Oncology
6.3.1. Global Real World Evidence Solutions Market, by Oncology, by Region, 2018 - 2030 (USD Billion)
6.4. Cardiovascular
6.4.1. Global Real World Evidence Solutions Market, by Cardiovascular, by Region, 2018 - 2030 (USD Billion)
6.5. Neurology
6.5.1. Global Real World Evidence Solutions Market, by Neurology, by Region, 2018 - 2030 (USD Billion)
6.6. Immunology
6.6.1. Global Real World Evidence Solutions Market, by Immunology, by Region, 2018 - 2030 (USD Billion)
6.7. Others
6.7.1. Global Real World Evidence Solutions Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Real World Evidence Solutions Market, by End-User
7.1. Key Findings
7.2. Introduction
7.2.1. Global Real World Evidence Solutions Market, by End-User, 2018 - 2030 (USD Billion)
7.3. Pharmaceutical and Medical Devices Companies
7.3.1. Global Real World Evidence Solutions Market, by Pharmaceutical and Medical Devices Companies, by Region, 2018 - 2030 (USD Billion)
7.4. Healthcare Providers
7.4.1. Global Real World Evidence Solutions Market, by Healthcare Providers, by Region, 2018 - 2030 (USD Billion)
7.5. Healthcare Payers
7.5.1. Global Real World Evidence Solutions Market, by Healthcare Payers, by Region, 2018 - 2030 (USD Billion)
7.6. Others
7.6.1. Global Real World Evidence Solutions Market, by Others , by Region, 2018 - 2030 (USD Billion)

8. Global Real World Evidence Solutions Market, by Geography

9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles
10.1. CLARIVATE PLC
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Clinigen Group plc
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Cognizant Technology Solutions Corporation
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Flatiron Health Inc.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. IBM Corporation
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. ICON plc
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. IQVIA Holdings Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Medpace Holdings Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Oracle Corporation
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. PAREXEL International Corporation
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. PerkinElmer Inc.
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. PPD Inc.
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development
10.13. SAS Institute Inc.
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Recent Development
10.14. Symphony Innovation LLC
10.14.1. Company Overview
10.14.2. Financial Performance
10.14.3. Product Benchmarking
10.14.4. Recent Development
10.15. SYNEOS HEALTH Inc.
10.15.1. Company Overview
10.15.2. Financial Performance
10.15.3. Product Benchmarking
10.15.4. Recent Development
10.16. UnitedHealth Group Incorporated
10.16.1. Company Overview
10.16.2. Financial Performance
10.16.3. Product Benchmarking
10.16.4. Recent Development

For more information about this report visit https://www.researchandmarkets.com/r/xwuskn


Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Cision
Cision

View original content:https://www.prnewswire.com/news-releases/global-real-world-evidence-solutions-market-2022-to-2030---share-size-trends-industry-analysis-report-301539423.html

SOURCE Research and Markets